نتایج جستجو برای: targeted gene therapy

تعداد نتایج: 1818842  

Journal: :Human molecular genetics 2001
M P Knauert P M Glazer

Sequence-specificity is the key to effective genetic targeting. With specificity, targeted genes can be manipulated in multiple ways; without it, gene therapy agents become loose canons within cells. Triplex forming oligonucleotides (TFOs) bind in the major groove of duplex DNA with high specificity and affinity. Because of these characteristics, TFOs have been proposed as homing devices for ge...

2015
Jonathan L. Dean Andrew R. Clark Christopher D. Buckley Jeremy Saklatvala Nicholas A. Morrice Claudia Monaco Helen E. Cunliffe Tina Tang Dalya R. Rosner Ewan A. Ross Tim Smallie Qize Ding John D. O'Neil John D. O’Neil Iva Klevernic Adam F. Cunningham

2012
Andrea Sartore-Bianchi Steffen Fieuws Silvio Veronese Mauro Moroni Nicola Personeni Milo Frattini Valter Torri Federico Cappuzzo Sara Vander Borght Vittoria Martin Margaret Skokan Armando Santoro Marcello Gambacorta Sabine Tejpar Marileila Varella-Garcia Salvatore Siena

Aims Epidermal growth factor receptor (EGFR) gene copy number evaluated by fluorescence in situ hybridisation (FISH) can discriminate among KRAS wild-type patients those with better outcome to EGFR-targeted therapy in metastatic colorectal cancer, further enhancing selection of patients. Nevertheless, enumeration of gene copies is challenging and the lack of analytical standardisation has limit...

2012
James S. Wilmott Richard A. Scolyer Georgina V. Long Peter Hersey

Recently, a CTLA-4 antibody and BRAF inhibitors showed survival benefits in advance melanoma treatment. The documentation of immune infiltrates in melanomas early during BRAF inhibitor therapy provides a scientific rationale for combination therapy with both treatments with possible synergistic benefits. This commentary reviews immune responses induced by BRAF inhibitors.

2010
Simone Mocellin Jeff Shrager Richard Scolyer Sandro Pasquali Daunia Verdi Francesco M. Marincola Marta Briarava Randy Gobbel Carlo Rossi Donato Nitti

BACKGROUND The efficacy of current anticancer treatments is far from satisfactory and many patients still die of their disease. A general agreement exists on the urgency of developing molecularly targeted therapies, although their implementation in the clinical setting is in its infancy. In fact, despite the wealth of preclinical studies addressing these issues, the difficulty of testing each t...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید